Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study
| Autor: | Bente L. Langdahl, Astrid Fahrleitner-Pammer, Gérald Rajzbaum, Östen Ljunggren, Heide Oertel, Clare Barker, Dimitrios Karras, Franz Jakob, Willem F. Lems, Annabel Barrett, James Bernard Walsh, Fernando Marin |
|---|---|
| Přispěvatelé: | Rheumatology, MOVE Research Institute, CCA - Innovative therapy |
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
Endocrinology Diabetes and Metabolism medicine.medical_treatment Osteoporosis Context (language use) Endocrinology Quality of life Internal medicine Teriparatide medicine Back pain Humans Prospective Studies Prospective cohort study Osteoporosis Postmenopausal Aged Bone Density Conservation Agents Diphosphonates business.industry Repeated measures design General Medicine Bisphosphonate medicine.disease Surgery Treatment Outcome Quality of Life Clinical Study Female Erratum medicine.symptom business medicine.drug |
| Zdroj: | European Journal of Endocrinology European Journal of Endocrinology, 166(1), 87-97. BioScientifica Ltd. Jakob, F, Oertel, H, Langdahl, B, Barrett, A, Karras, D, Walsh, J B, Fahrleitner-Pammer, A, Razjbaum, G, Barker, C, Lems, W F & Marin, F 2012, ' Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36 month results from the European Forsteo Observational Study ', European Journal of Endocrinology, vol. 166, no. 1, pp. 87-97 . https://doi.org/10.1530/EJE-11-0740 |
| ISSN: | 1479-683X 0804-4643 |
| DOI: | 10.1530/EJE-11-0740 |
| Popis: | ObjectivesTo describe fracture rates, back pain, and health-related quality of life (HRQoL) in postmenopausal women with osteoporosis and prior bisphosphonate therapy, treated with teriparatide for up to 18 months and followed up for a further 18 months.DesignProspective, multinational, and observational study.MethodsData on prior bisphosphonate use, clinical fractures, back pain visual analog scale (VAS), and HRQoL (EQ-5D) were collected over 36 months. Fracture data were summarized in 6-month intervals and analyzed using logistic regression with repeated measures. Changes from baseline in back pain VAS and EQ-VAS were analyzed using a repeated measures model.ResultsOf the 1581 enrolled patients with follow-up data, 1161 (73.4%) had a history of prior bisphosphonate use (median duration: 36 months). Of them, 169 (14.6%) sustained ≥1 fracture during 36-month follow-up. Adjusted odds of fracture were significantly decreased at each 6-month interval compared with the first 6 months of teriparatide treatment: 37% decrease in the 12 to P=0.03) and a 76% decrease in the 12- to 18-month period after teriparatide was discontinued (PConclusionsPostmenopausal women with severe osteoporosis previously treated with bisphosphonates had a significant reduction in the incidence of fractures compared with the first 6 months of therapy, a reduction in back pain and an improvement in HRQoL during up to 18 months of teriparatide treatment. These outcomes were still evident for at least 18 months after teriparatide was discontinued. The results should be interpreted in the context of an uncontrolled, observational study in a routine clinical setting. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|